Business Wire

MBZIRC

28.9.2021 13:46:05 CEST | Business Wire | Press release

Share
Abu Dhabi’s ASPIRE Launches Over US$3 Million MBZIRC Maritime Grand Challenge

The Mohamed Bin Zayed International Robotics Challenge (MBZIRC) will be held in the UAE capital, Abu Dhabi, in June 2023, where tech innovators will participate to seek marine safety and security solutions to take home more than US$3 million in prize money.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210928005641/en/

Organised by ASPIRE, the dedicated technology programme management pillar of the Advanced Technology Research Council (ATRC), the overarching advanced technology research body in Abu Dhabi, UAE, the MBZIRC is held every two years. The upcoming edition, called MBZIRC Maritime Grand Challenge, focuses on real-time solutions to maritime safety and security challenges and seeks to claim its place among the largest and most prestigious AI and robotics competitions in the world.

The Challenge is open to international universities, research institutions, companies and individual innovators from all over the world. It will involve a heterogeneous collaboration among unmanned aerial vehicles and unmanned surface vehicles, to perform complex navigation and manipulation tasks in a GNSS-denied environment. Call for registrations is now open.

Commenting on the announcement, H.E. Faisal Al Bannai , Secretary General of ATRC, said: “We are proud that MBZIRC is going global by inviting the best talent from all over the world to participate. We have set a tough real-world challenge that will push the participants to the limits of their capabilities. The event is a great opportunity to demonstrate the pioneering scientific research work that is taking place in Abu Dhabi and the UAE.”

The challenge will show how both entities focus on niche areas of technology, while attracting global innovators to stimulate ideas, encourage collaboration, and push boundaries in advanced technologies to find systems solutions to global challenges.

“For countries with long coastlines, ensuring maritime safety requires significant investment in sophisticated equipment and highly trained personnel. Using advanced robotic systems can not only help reduce costs, but also handle some of the often- dangerous tasks performed by humans. The motivation for holding the MBZIRC Maritime Grand Challenge is to take the technology out of the laboratory and test it in a real-world environment to see what is possible,” said Dr Arthur Morrish, Chief Executive of ASPIRE.

Dr Morrish underscored the two-fold purpose behind the competition: one is to focus on the important problems in autonomy of robotics while engaging the world community in a hard robotics challenge. The other is to find a solution to a real-world challenge facing the world.

The challenge is for a swarm of UAVs to identify a target vessel from several similar vessels in open waters in a GNSS-denied environment, and to offload specific items from the target onto an USV in the shortest possible time using autonomous technologies. This is a new kind of kind of exercise in autonomous robotics. “A nice thing about this challenge is that you tell people what you want, but you don’t specify an approach to do it,” Dr Morrish added.

He said that this kind of a smart system will have practical application in other areas as well, especially as it can perform complex tasks of autonomous intervention in a GNSS-denied environment.

For more information, visit www.mbzirc.com

*Source: AETOSWire

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release

New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu

Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release

Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope

Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release

Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co

SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release

The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release

Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye